Llwytho...
The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration
Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Int J Physiol Pathophysiol Pharmacol |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
e-Century Publishing Corporation
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/ https://ncbi.nlm.nih.gov/pubmed/26823960 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|